Search results
Results from the WOW.Com Content Network
We need a new approach to Alzheimer’s and all other diseases that cause dementia. We do need effective drug treatments. But short of cures, patients need services and supports.
An estimated 6.7 million Americans ages 65 and older were living with Alzheimer’s in 2023, according to the Alzheimer’s Association. The number is projected to increase to 13.8 million by 2060.
Aducanumab, sold under the brand name Aduhelm, is a monoclonal antibody designed to treat Alzheimer's disease. [2] [3] It is a monoclonal antibody [3] [2] that targets aggregated forms (plaque) [4] [5] of amyloid beta (Aβ) found in the brains of people with Alzheimer's disease to reduce its buildup.
This Dec. 21, 2022 image provided by Eisai in January 2023, shows vials and packaging for their medication Leqembi. On Friday, Jan. 6, 2023, U.S. health officials approved Leqembi, a new Alzheimer ...
Crenezumab was developed by Ruth Greferath, Ph.D., and Claude Nicolau, Ph.D., before the Swiss-based biopharmaceutical company AC Immune was founded, which focuses on developing targeted therapeutics for misfolded proteins that cause neurodegenerative diseases, such as Alzheimer's and Parkinson's disease. [4]
August Wilson (né Frederick August Kittel Jr.; April 27, 1945 – October 2, 2005) was an American playwright. He has been referred to as the "theater's poet of Black America". [ 1 ] He is best known for a series of 10 plays, collectively called The Pittsburgh Cycle (or The Century Cycle ) , which chronicle the experiences and heritage of the ...
The Food and Drug Administration has approved lecanemab, a drug developed by Eisai and Biogen with the goal of slowing the progression of Alzheimer’s disease. FDA grants full approval to new ...
Jitney is a play by American playwright August Wilson. The eighth in his " Pittsburgh Cycle ", this play is set in a worn-down gypsy cab station in Pittsburgh, Pennsylvania , in early autumn 1977. The play premiered on Broadway in 2017.